Blake Olmsted, MD
Allergy & Immunology · Hattiesburg, MSNPI 1780948216
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 452 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,825, 3.2 times the $578 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in MS, where the typical reported total is $10,118.
Across 452 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$1K
- AstraZeneca$1K
- CSL Behring$738
- Genentech USA, Inc.$504
- Novartis$436
- plus $2K from 27 others
What the payments were for
- Food & beverage$8,10297%
- Education$2623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 97 | $1,910 |
| GSK | 117 | $1,364 |
| AstraZeneca | 56 | $1,254 |
| CSL Behring | 36 | $738 |
| Genentech USA, Inc. | 25 | $504 |
| Novartis | 22 | $436 |
| Amgen | 15 | $379 |
| Sanofi | 9 | $238 |
| Kaleo, Inc. | 11 | $214 |
| Octapharma USA, Inc. | 10 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $160 |
| Biocryst US Sales Co., LLC | 5 | $114 |
| Pfizer | 4 | $100 |
| Optinose US, Inc. | 5 | $83 |
| Aimmune Therapeutics, Inc. | 3 | $82 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $79 |
| USWM, LLC | 3 | $77 |
| LEO Pharma Inc. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $60 |
| Ionis Pharmaceuticals, Inc. | 2 | $54 |
| Incyte Corporation | 2 | $37 |
| Merck | 1 | $33 |
| Organon | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Biocryst Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$8,364 in reported general payments places this provider in the 45th percentile of 28 allergy & immunology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 27 | $103,488 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $35,492 |
| Ipratropium Bromide | 412 | $12,892 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,344 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,411 |
| Azelastine Hcl | 250 | $6,686 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,626 |
| Epinephrine | 21 | $4,285 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,098 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $3,106 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $2,110 |
| Fluticasone Propionate | 126 | $1,311 |
| Montelukast Sodium | 172 | $995 |
| Levocetirizine Dihydrochloride | 39 | $656 |
| Prednisone | 55 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,364 | $44,83677 claims |
| AstraZenecaSymbicort | $1,254 | $7,41121 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $4,28521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 28 allergy & immunology providers in Mississippi.
Other allergy & immunology in Hattiesburg
- Kathryn McMullanHattiesburg$10K
- Charlene BroomeHattiesburg$6K
- Taylor MabryHattiesburg$2K
- Marlee WadsworthHattiesburg$2K
- Todd AdkinsJackson$226K
- Patricia StewartMadison$215K
- Daniel VenarskeJackson$156K
- Dexter WalcottJackson$154K
- Chelle WilhelmJackson$61K
- Mark MurrayDiberville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.